Gil Lichtshein
Psychiatry · Boca Raton, FLNPI 1245334622
Payments from drug & device makers
Across 167 payments — averaging $60.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Neuronetics, Inc.$6K
- Takeda Pharmaceuticals U.S.A., Inc.$2K
- Supernus Pharmaceuticals, Inc.$508
- AbbVie$503
- Corium, LLC$477
- Axsome Therapeutics, Inc.$462
- plus $707 from 11 others
What the payments were for
- Consulting fees$1,40014%
- Food & beverage$3,29332%
- Education$470%
- Other$5,41553%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Neuronetics, Inc. | 7 | $5,625 |
| Takeda Pharmaceuticals U.S.A., Inc. | 26 | $1,874 |
| Supernus Pharmaceuticals, Inc. | 21 | $508 |
| AbbVie(2 entities) | 35 | $503 |
| Corium, LLC | 28 | $477 |
| Axsome Therapeutics, Inc. | 15 | $462 |
| Ironshore Pharmaceuticals Inc. | 7 | $160 |
| Alkermes, Inc. | 8 | $131 |
| Bausch Health US, LLC | 6 | $98 |
| Collegium Pharmaceutical, Inc. | 4 | $74 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 2 | $63 |
| Shire North American Group Inc | 2 | $44 |
| Neos Therapeutics, LP | 2 | $38 |
| Neurocrine Biosciences, Inc. | 1 | $36 |
| Lilly USA, LLC | 1 | $23 |
| Johnson & Johnson | 1 | $21 |
| Noven Therapeutics, LLC | 1 | $20 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NEUROSTAR TMS THERAPY SYSTEM$5,415
- TRINTELLIX$1,400
- Auvelity$240
- QELBREE$114
How this compares
$10,155 in reported general payments places this provider in the 85th percentile of 2,059 psychiatry providers in Florida.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| SpravatoEsketamine Hcl | 19 | $68,785 |
| AuvelityDextromethorphan Hbr/Bupropion | 16 | $18,274 |
| Adderall XrDextroamphetamine/Amphetamine | 11 | $2,371 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 28 | $1,249 |
| Alprazolam | 114 | $1,076 |
| Olanzapine | 31 | $739 |
| Bupropion XlBupropion Hcl | 30 | $599 |
| Vilazodone Hcl | 12 | $548 |
| Clonazepam | 50 | $511 |
| Sertraline Hcl | 38 | $488 |
| Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine | 11 | $418 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 23 | $397 |
| Fluoxetine Hcl | 26 | $354 |
| Trazodone Hcl | 23 | $289 |
| Zolpidem Tartrate | 23 | $275 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonSpravato | $21 | $68,78519 claims |
| Axsome Therapeutics, Inc.Auvelity | $462 | $18,27416 claims |
| Lilly USA, LLCOlanzapine | $23 | $73931 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,059 psychiatry providers in Florida.
Other psychiatry in Boca Raton
- Theodore TreeseBoca Raton$8.5M
- Richard JacksonBoca Raton$4.1M
- Edwin GomezWeston$24.9M
- Rishi KakarTamarac$23.9M
- Peter VentreOakland Park$18.7M
- Jose GamezHialeah$14.8M
- John JoyceJacksonville$13.6M
- Silvia Silva-DulucMiami$11.7M
- Kelley WilsonTampa$11.1M
- Emilio Mantero-AtienzaMiami Beach$10.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.